Although biotechnology investors and preclinical pharmacology
experts may not always concur, peptide therapeutics offer
demonstrable commercial success [1]. More than 50 peptide
drugs, with annual sales in excess of $1 billion each, were marketed
in 2010. Primary therapeutic indications include ...
With central research and development funding at an all-time low in the United States [1], early biotech investors tend to target low investment projects with the expectation of a 30× return from their few successful ventures.
The success rates of drugs during various phases of the clinical development pipeline are crucial benchmarks for valuation models in the pharmaceutical investment community.